论文部分内容阅读
目的比较雷贝拉唑与奥美拉唑三联疗法治疗幽门螺杆菌(helicobacter pylori,Hp)阳性消化性溃疡的临床疗效。方法 2009年1-12月将96例Hp阳性的消化性溃疡及慢性胃炎患者,根据治疗方法不同随机分为雷贝拉唑组(52例)和奥美拉唑组(44例)。两组联合的抗菌药均为克拉霉素和阿莫西林,疗程1周。各组在治疗后4～8周分别检测Hp感染情况,并观察溃疡的愈合情况。结果雷贝拉唑组Hp根除率及3d症状缓解率分别为96.2%(50/52)、82.7%(43/52),奥美拉唑组分别为88.6%(39/44)、72.7%(32/44),雷贝拉唑组均明显高于奥美拉唑组(P<0.05)。雷贝拉唑组溃疡愈合率为98.1%(51/52),与奥美拉唑组的95.5%(42/44)比较无统计学意义(P>0.05)。结论雷贝拉唑联合克拉霉素和阿莫西林是根除Hp比较有效的一种治疗方案。
Objective To compare the clinical efficacy of rabeprazole and omeprazole triple therapy in the treatment of helicobacter pylori (Hp) -positive peptic ulcer. Methods From January to December 2009, 96 patients with Hp-positive peptic ulcer and chronic gastritis were randomly divided into rabeprazole group (n = 52) and omeprazole group (n = 44) according to the different treatment methods. The two groups of antibacterials were clarithromycin and amoxicillin for one week. Hp infection was detected in each group 4 to 8 weeks after treatment, and healing of the ulcer was observed. Results The rates of eradication and 3d remission of Hp in rabeprazole group were 96.2% (50/52) and 82.7% (43/52), respectively. The omeprazole group was 88.6% (39/44) and 72.7% 32/44), rabeprazole group were significantly higher than omeprazole group (P <0.05). The rate of ulcer healing in rabeprazole group was 98.1% (51/52), which was not statistically significant compared with 95.5% (42/44) in omeprazole group (P> 0.05). Conclusion Rabeprazole combined with clarithromycin and amoxicillin is a more effective treatment of Hp eradication.